{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T19:23:57Z","timestamp":1648581837778},"reference-count":46,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tierarztl Prax Ausg K Kleintiere Heimtiere"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n               Objective A number of different rescue protocols for relapsed canine multicentric large-cell lymphoma have been described. The aim of this pilot study was to evaluate the efficacy of a maintenance treatment in dogs that experienced a second complete remission after a short L-CHOP-rescue protocol.<\/jats:p><jats:p>\n               Material and methods Included in the study were dogs experiencing the first lymphoma relapse during a treatment-free period which were treated with a short L-CHOP protocol, achieved a complete remission and were afterwards treated with a continuous maintenance phase (MP) protocol. The L-CHOP protocol consisted of weekly treatments, with at least 3\u2005additional treatments following complete remission. Thereafter the MP protocol with 2-week treatment intervals was conducted. It consisted of alternating oral home administration of different alkylating agents and one intravenously administered cytotoxic agent of a different mechanism of action. The dogs were presented either every 4 or 6\u2005weeks for intravenous treatment and at this time a complete blood count was performed. The durations of the first remission, disease-free interval and overall survival time were evaluated.<\/jats:p><jats:p>\n               Results A total of 20 dogs were included in the study. A median of 7 weekly applications were given before the treatment was switched to the MP protocol. During MP, 14\u2005dogs were treated intravenously every 6\u2005weeks and 6\u2005dogs every 4\u2005weeks. Haematological adverse events were mainly mild. During the L-CHOP-protocol, one septic event occurred, and 2\u2005dogs were hospitalized due to gastrointestinal adverse events. No patient required hospitalization during the MP. Fifteen dogs completed at least one cycle in the MP and a median of 8.5 chemotherapeutic treatments were administered. The median disease-free interval was 264\u2005days and the median overall survival time was 737\u2005days.<\/jats:p><jats:p>\n               Conclusion and clinical relevance The protocol was generally well tolerated. Since 5 patients showed disease progression during the first cycle of the MP, dogs should ideally be evaluated for minimal residual disease before being switched to the MP. The case number in the presented study was low and the treatment relatively heterogeneous. Therefore, more dogs have to be treated with the proposed protocol before general recommendations can be made.<\/jats:p>","DOI":"10.1055\/a-1481-7066","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T22:30:59Z","timestamp":1624401059000},"page":"185-194","source":"Crossref","is-referenced-by-count":0,"title":["Maintenance treatment in relapsed canine lymphoma after a short L-CHOP protocol"],"prefix":"10.1055","volume":"49","author":[{"given":"Karin","family":"Troedson","sequence":"additional","affiliation":[{"name":"Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, LMU Munich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliia","family":"Ignatenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csilla","family":"Fejos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury","family":"Zablotski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Hirschberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hon.2017","article-title":"The dog as a possible animal model for human non-Hodgkin lymphoma: a review","volume":"31","author":"L Marconato","year":"2013","journal-title":"Hematol Oncol"},{"key":"ref2","first-page":"120","article-title":"Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"14","author":"R Chun","year":"2000","journal-title":"J\u2005Vet Intern Med"},{"issue":"S 01","key":"ref3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/vco.12163","article-title":"Retrospective analysis for treatment of naive canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol","volume":"14","author":"K Curran","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"ref4","first-page":"704","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"L D Garrett","year":"2002","journal-title":"J\u2005Vet Intern Med"},{"key":"ref5","first-page":"348","article-title":"Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma","volume":"15","author":"A S Moore","year":"2001","journal-title":"J\u2005Vet Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1476-5829.2010.00224.x","article-title":"Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs","volume":"8","author":"K M Rassnick","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1476-5829.2010.00230.x","article-title":"CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma","volume":"9","author":"R B Rebhun","year":"2011","journal-title":"Vet Comp Oncol"},{"key":"ref8","first-page":"948","article-title":"Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol","volume":"20","author":"D Simon","year":"2006","journal-title":"J\u2005Vet Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/vr.c5081","article-title":"Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs","volume":"167","author":"I Zenker","year":"2010","journal-title":"Vet Rec"},{"key":"ref10","first-page":"271","article-title":"Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma","volume":"57","author":"S L Wang","year":"2016","journal-title":"Can Vet J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1476-5829.2011.00311.x","article-title":"Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma","volume":"11","author":"J W Elliott","year":"2013","journal-title":"Vet Comp Oncol"},{"key":"ref12","first-page":"1355","article-title":"Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma","volume":"21","author":"K Hosoya","year":"2007","journal-title":"J\u2005Vet Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1476-5810.2003.00027.x","article-title":"A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma","volume":"1","author":"K E Morrison-Collister","year":"2003","journal-title":"Vet Comp Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2460\/javma.238.4.501","article-title":"Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000\u20132007)","volume":"238","author":"A B Flory","year":"2011","journal-title":"J\u2005Am Vet Med Assoc"},{"key":"ref15","first-page":"1364","article-title":"Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma","volume":"21","author":"K M Rassnick","year":"2007","journal-title":"J\u2005Vet Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/vr.104077","article-title":"Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma","volume":"180","author":"E M Lautscham","year":"2017","journal-title":"Vet Rec"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2460\/javma.232.6.879","article-title":"Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma","volume":"232","author":"D Simon","year":"2008","journal-title":"J\u2005Am Vet Med Assoc"},{"key":"ref18","first-page":"127","article-title":"Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma","volume":"21","author":"C F Saba","year":"2007","journal-title":"J\u2005Vet Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) \u2013 a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"D M Vail","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Veterinary cooperative oncology group \u2013 common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","author":"[Anonym]","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"ref21","first-page":"354","article-title":"Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma","volume":"10","author":"P J Bergman","year":"1996","journal-title":"J\u2005Vet Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/(sici)1097\u20130142(19960501)\u200b77:9<1892::aidL42:DASHcncr20>3.0.co;2","article-title":"P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance","volume":"77","author":"J J Lee","year":"1996","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1892\/0891-6640(2006)20[1166:\u200bteogoc]2.0.co;2","article-title":"The effect of glucocorticoids on canine lymphocyte marker expression and apoptosis","volume":"20","author":"M A Ammersbach","year":"2006","journal-title":"J\u2005Vet Intern Med"},{"key":"ref24","first-page":"182","volume-title":"Cancer Chemotherapy","author":"D Gustafson","year":"2019"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0305-7372(83)80029-2","article-title":"4\u2019-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data","volume":"10","author":"F Ganzina","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/030089168507100304","article-title":"Clinical toxicity of 4\u2019-epi-doxorubicin (epirubicin)","volume":"71","author":"F Ganzina","year":"1985","journal-title":"Tumori"},{"key":"ref27","first-page":"121","article-title":"The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin","volume":"128","author":"P Tham","year":"1987","journal-title":"Am J Pathol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1476-5829.2009.00199.x","article-title":"Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma","volume":"8","author":"A T Daters","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2460\/javma.254.2.236","article-title":"Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate-to large-cell lymphoma","volume":"254","author":"T M Marquardt","year":"2019","journal-title":"J\u2005Am Vet Med Assoc"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/vco.12051","article-title":"Determination of MDR1 gene expression for prediction of chemotherapy tolerance and treatment outcome in dogs with lymphoma","volume":"13","author":"I Gramer","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1939-1676.2011.0730.x","article-title":"Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma","volume":"25","author":"E Warry","year":"2011","journal-title":"J\u2005Vet Intern Med"},{"key":"ref32","first-page":"1637","article-title":"Pharmacokinetics of the absorption, distribution, and elimination of melphalan in the dog","volume":"61","author":"R L Furner","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/vco.12433","article-title":"Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma","volume":"16","author":"K Harding","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jsap.12500","article-title":"Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014)","volume":"57","author":"J A Lenz","year":"2016","journal-title":"J\u2005Small Anim Pract"},{"key":"ref35","volume-title":"Principles of medical oncology","author":"E DVJ Chu","year":"2005"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/jvim.14895","article-title":"Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy","volume":"32","author":"Q Fournier","year":"2018","journal-title":"J\u2005Vet Intern Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/vco.12009","article-title":"Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case-control study","volume":"12","author":"R Gaeta","year":"2014","journal-title":"Vet Comp Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2460\/javma.249.12.1408","article-title":"Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55\u2005cases (2009\u20132015)","volume":"249","author":"C M Chan","year":"2016","journal-title":"J\u2005Am Vet Med Assoc"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/vco.12292","article-title":"Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide","volume":"15","author":"L Setyo","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tvjl.2010.04.013","article-title":"Veterinary and toxicological applications for the detection of cardiac injury using cardiac troponin","volume":"185","author":"M Serra","year":"2010","journal-title":"Vet J"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/vco.12048","article-title":"Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation","volume":"13","author":"L Aresu","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/vco.12374","article-title":"Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour","volume":"16","author":"M Cozzi","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fvets.2015.00042","article-title":"Transformation of Canine Lymphoma\/Leukemia to More Aggressive Diseases: Anecdotes or Reality?","volume":"2","author":"S Comazzi","year":"2015","journal-title":"Front Vet Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/vco.12453","article-title":"Minimal residual disease in lymph nodes after achievement of complete remission predicts time to relapse in dogs with large B-cell lymphoma","volume":"17","author":"C Chalfon","year":"2019","journal-title":"Vet Comp Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.tvjl.2014.03.006","article-title":"Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma","volume":"200","author":"L Aresu","year":"2014","journal-title":"Vet J"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2460\/javma.238.4.480","article-title":"Predictors of long-term survival in dogs with high-grade multicentric lymphoma","volume":"238","author":"L Marconato","year":"2011","journal-title":"J\u2005Am Vet Med Assoc"}],"container-title":["Tier\u00e4rztliche Praxis Ausgabe K: Kleintiere \/ Heimtiere"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1481-7066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T22:31:51Z","timestamp":1624401111000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1481-7066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":46,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2021,6,22]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1481-7066","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1434-1239","2567-5842"],"issn-type":[{"value":"1434-1239","type":"print"},{"value":"2567-5842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}